Abstract
Developmental and epileptic encephalopathies (DEEs) are a heterogenous group of epilepsies in which altered brain development leads to developmental delay and seizures, with the epileptic activity further negatively impacting neurodevelopment. Identifying the underlying cause of DEEs is essential for progress toward precision therapies. Here we describe a group of individuals with biallelic variants in DENND5A and determine that variant type is correlated with disease severity. We demonstrate that DENND5A interacts with MUPP1 and PALS1, components of the Crumbs apical polarity complex, which is required for both neural progenitor cell identity and the ability of these stem cells to divide symmetrically. Induced pluripotent stem cells lacking DENND5A fail to undergo symmetric cell division during neural induction and have an inherent propensity to differentiate into neurons, and transgenic DENND5A mice, with phenotypes like the human syndrome, have an increased number of neurons in the adult subventricular zone. Disruption of symmetric cell division following loss of DENND5A results from misalignment of the mitotic spindle in apical neural progenitors. A subset of DENND5A is localized to centrosomes, which define the spindle poles during mitosis. Cells lacking DENND5A orient away from the proliferative apical domain surrounding the ventricles, biasing daughter cells towards a more fate-committed state and ultimately shortening the period of neurogenesis. This study provides a mechanism behind DENND5A-related DEE that may be generalizable to other developmental conditions and provides variant-specific clinical information for physicians and families.
Competing Interest Statement
KM and RP are employed by GeneDx, LLC. All other authors report no conflicts of interest.
Funding Statement
Participant 10 was recruited as part of the German-Jordanian Autosomal Recessive Intellectual Disability project (GeJo-ARID) funded by the German Academic Exchange Service (DAAD) as part of the German-Arab Transformation Program Line4 (Project-ID 57166498). This work was funded by a Foundation Grant from the Canadian Institutes of Health Research to PSM and a grant from the Alain and Sandra Bouchard Foundation for Intellectual Disabilities to PSM and TMD. This work was also supported by the King Salman Center for Disability Research through Research Group no RG-2022-010 (FSA). This work was also performed under the Care4Rare Canada Consortium funded by Genome Canada and the Ontario Genomics Institute (OGI-147), the Canadian Institutes of Health Research, Ontario Research Fund, Genome Alberta, Genome British Columbia, Genome Quebec, and Childrens Hospital of Eastern Ontario Foundation (DC, ESYG, MO). Research reported in this manuscript was also supported by the NIH Common Fund, through the Office of Strategic Coordination/Office of the NIH Director under Award Number(s) [U01HG007672, U01HG007943] (HC) and [NS105078, HG011758] (JRL).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All materials and methods for participant recruitment and clinical data collection was approved by the McGill University Health Centre research ethics board (study 2021-6324) and the McGill Faculty of Medicine and Health Sciences institutional review board (study A12-M66-21B).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵† The full list of authors in network is in Supplementary Notes.
This version of the manuscript includes a new participant and one new author, and incorporates changes that address reviewer comments from a peer-reviewed journal for which this manuscript is currently under review. Changes include a slight rewording of the title, defining participant seizure types, quantifying neurological and developmental phenotypes, overexpressing GFP-DENND5A in NPCs, and showing individual data points on all main figure graphs and charts.
Data availability
Raw data and statistical analyses for all major experiments are provided in Source Data. All identified spectra from the mass spectrometry experiment are available in Source Data, and raw proteomic data is available on PRIDE (PXD048699). Data concerning in vitro experiments and in vivo and ex vivo mouse experiments were generated at the Montreal Neurological Institute of McGill University. Data concerning zebrafish experiments were generated at the Oklahoma Medical Research Foundation. Derived data supporting any other findings of this study are available upon reasonable request from the corresponding author.
